ReviewFrontiers in immunology2015
Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Sublingual immunotherapy for 4 years increased the number of Foxp3Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Trial
- Article
- The Yin and Yang of Type 1 Regulatory T Cells: From Discovery to Clinical Application.Frontiers in immunology · 2021Review
- Type 1 diabetes mellitus and its oral tolerance therapy.World journal of diabetes · 2020Review
- Directed differentiation of regulatory T cells from naive T cells and prevention of their inflammation-mediated instability using small molecules.Clinical and experimental immunology · 2020Article
- Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.Frontiers in immunology · 2020Review
- Decreased number and impaired function of type 1 regulatory T cells in autoimmune diseases.Journal of cellular physiology · 2019Review
- Phosphatase inhibitor PPP1R11 modulates resistance of human T cells toward Treg-mediated suppression of cytokine expression.Journal of leukocyte biology · 2019Article
- Mdivi-1, a mitochondrial fission inhibitor, modulates T helper cells and suppresses the development of experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2019Article
- Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.Frontiers in immunology · 2019Review
- Reprogrammed CD4Frontiers in immunology · 2019Article
- Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3.BMC biology · 2018Article
- Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression.Scientific reports · 2018Article
- Combination Therapy Is the New Gene Therapy?Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Early Growth Response Gene 2-Expressing CD4Frontiers in immunology · 2018Review
- Engineered T Regulatory Type 1 Cells for Clinical Application.Frontiers in immunology · 2018Review
- Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside.Frontiers in immunology · 2018Review
- Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.Frontiers in immunology · 2018Review
- IL-10-Engineered Human CD4Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.